Biden's limit on drug industry middlemen backfires, pharmacists say
The Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring, pharmacists say. Instead, it’s adding to the woes of the independent drugstores it was partly designed to help. The so-called PBMs have long clawed back a […]
